Minicircle to Sell Unregulated Klotho Minicircle DNA Therapy in Honduras Starting 2026

{"The therapy uses episomal minicircle DNA injected into abdominal fat to drive transient expression of the klotho protein. In mice, lifelong klotho overexpression extends median lifespan by up to 30 percent; a single published primate study showed memory gains after protein infusion. Minicircle’s only human data come from an unpublished 24-person proof-of-concept exercise conducted at partner clinics in Próspera, Honduras, and Paradise Island, Bahamas, with results promised but not yet released.","This move exemplifies regulatory arbitrage that has accelerated since 2020 as multiple longevity startups relocate dosing to jurisdictions offering “innovation-friendly” frameworks. It parallels earlier cases of unapproved AAV and plasmid therapies sold in Georgia and Mexico, where adverse-event reporting remains voluntary. The absence of integration reduces some genomic risks, yet the $300,000-plus cost and one-year claimed durability create strong incentives for repeat dosing without longitudinal safety monitoring.","Ethicists note that excess klotho in a rare pediatric over-expression syndrome produced hypophosphatemic rickets and growth failure, underscoring dose-dependent harm. No large-animal toxicology package or standardized immunogenicity assay has been disclosed. Strengthening evidence would require a registered Phase 1/2 trial with pre-specified biomarkers, independent data monitoring, and at least 12-month follow-up in a regulated jurisdiction.","Minicircle’s strategy tests whether first-mover commercial availability can outpace slow-moving regulators; the next twelve months will reveal whether demand materializes or whether adverse-event clusters force jurisdictions to close the loophole."}